CANCER:

Male Breast Cancer

Related cancers:

‹

Breast Cancer (1771)

HER2 Negative Breast Cancer (356)

HER2 Positive Breast Cancer (350)

Hormone Receptor Positive Breast Cancer (275)

Triple Negative Breast Cancer (264)

Estrogen Receptor Positive Breast Cancer (177)

Hormone Receptor Negative Breast Cancer (4)

Breast Cancer (1771)

HER2 Negative Breast Cancer (356)

HER2 Positive Breast Cancer (350)

Hormone Receptor Positive Breast Cancer (275)

Triple Negative Breast Cancer (264)

Estrogen Receptor Positive Breast Cancer (177)

Hormone Receptor Negative Breast Cancer (4)

›

HR positive + HER-2 negative HR positive + HER-2 negative	Male Breast Cancer Male Breast Cancer	HR positive + HER-2 negative HR positive + HER-2 negative	Male Breast Cancer Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline	tamoxifen Sensitive: A2 - Guideline
No biomarker No biomarker	Male Breast Cancer Male Breast Cancer	No biomarker No biomarker	Male Breast Cancer Male Breast Cancer	HER2 inhibitor Sensitive: A2 - Guideline	HER2 inhibitor Sensitive: A2 - Guideline
HR positive + HER-2 negative HR positive + HER-2 negative	Male Breast Cancer Male Breast Cancer	HR positive + HER-2 negative HR positive + HER-2 negative	Male Breast Cancer Male Breast Cancer	fulvestrant Sensitive: A2 - Guideline	fulvestrant Sensitive: A2 - Guideline
HR positive HR positive	Male Breast Cancer Male Breast Cancer	HR positive HR positive	Male Breast Cancer Male Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline	Aromatase inhibitor Sensitive: A2 - Guideline
HR positive HR positive	Male Breast Cancer Male Breast Cancer	HR positive HR positive	Male Breast Cancer Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline	tamoxifen Sensitive: A2 - Guideline
ER positive ER positive	Male Breast Cancer Male Breast Cancer	ER positive ER positive	Male Breast Cancer Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline	tamoxifen Sensitive: A2 - Guideline
PIK3CA mutation + HR positive + HER-2 negative PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer Male Breast Cancer	PIK3CA mutation + HR positive + HER-2 negative PIK3CA mutation + HR positive + HER-2 negative	Male Breast Cancer Male Breast Cancer	alpelisib Sensitive: A2 - Guideline	alpelisib Sensitive: A2 - Guideline
HR positive + HER-2 negative HR positive + HER-2 negative	Male Breast Cancer Male Breast Cancer	HR positive + HER-2 negative HR positive + HER-2 negative	Male Breast Cancer Male Breast Cancer	ribociclib Sensitive: B - Late Trials	ribociclib Sensitive: B - Late Trials
HR positive + HER-2 negative HR positive + HER-2 negative	Male Breast Cancer Male Breast Cancer	HR positive + HER-2 negative HR positive + HER-2 negative	Male Breast Cancer Male Breast Cancer	palbociclib Sensitive: C3 – Early Trials	palbociclib Sensitive: C3 – Early Trials